Menopause
Conference Coverage
REPLENISH: Oral estradiol/progesterone slowed bone turnover as it cut VMS
From the Journals
Fezolinetant safe, effective for menopausal vasomotor symptoms
The elective neurokinin 3 receptor antagonist appears to be an effective nonhormone treatment for moderate to severe vasomotor symptoms associated...
Conference Coverage
Beginning estrogen soon after menopause slows atherosclerosis progression
PHOENIX – The study raises a critical question: Is there a time period where getting hormone therapy would be most beneficial for the heart?
Conference Coverage
Menopause hormone therapy found to delay type 2 diabetes
LOS ANGELES – Transdermal delivery of estrogen is the preferred means of administration in women who are obese, who have a risk of DVT, or who...
Latest News
Bisphosphonates turn 50
ORLANDO – The progress seen in treating postmenopausal women with breast cancer, is not evident in younger, premenopasual women or for other...
Guidelines
Try testosterone for some women with sexual dysfunction, but not others
Evidence does not support testosterone use for other conditions, and concentrations should mirror premenopausal physiological conditions.
From the Journals
Higher BMD linked to family history of diabetes in postmenopausal women
The connection may be related to insulin resistance.
Conference Coverage
Transdermal estradiol may modulate the relationship between sleep, cognition
LOS ANGELES – Women using the patch fared better in all measures than did those taking oral conjugated equine estrogen.
Opinion
Discuss compounded bioidentical hormones and cancer risk
Patients who desire compounded bioidentical hormone preparations should be counseled that little is known about the safety of these preparations,...
News
Romosozumab gets FDA approval for treating osteoporosis
The pair of injections mainly works by encouraging new bone formation.
Conference Coverage
Fezolinetant looks good for hot flashes in phase 2b trial
NEW ORLEANS – Big reductions in vasomotor symptoms were seen despite a strong placebo response for this nonhormonal therapy.